Agenus Q3 2024 net loss $67.2M, cash $44.8M; BOT/BAL shows MSS CRC promise

AGENUS INC

2024-Q3 EPS reported -$8.65 revenue$76,626,000

Cash $44.8M at Sept 30, 2024 (vs $76.1M Dec 2023); raised $7.1M via ATM post-quarter.
Q3 2024 revenue $25.1M (non-cash); net loss $67.2M; cash used in ops 9M 2024 $129.7M (down from $183.8M YoY).
BOT/BAL combination shows unprecedented outcomes in neoadjuvant MSS CRC (ESMO GI 2024) and advanced sarcomas (ESMO 2024).
Strategic initiatives: real estate monetization discussions advancing; near-term transaction expected to deliver substantial resources.
EMA agreement on dose selection and trial design for Phase 3 study in MSS CRC.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.